Skip to content

The Effect of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus

The Effects of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus: A Randomized Clinical Trials

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02845024
Enrollment
24
Registered
2016-07-26
Start date
2014-09-30
Completion date
2016-07-31
Last updated
2016-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus With Periodontal Disease

Brief summary

Aim: The purpose of this study is to investigate the effect of nonsurgical periodontal therapy plus doxycycline on glycemic control in type 2 diabetes mellitus (type 2 DM) patients who have periodontitis. Materials and methods: A total of 24 type 2 DM patients with periodontitis will be selected for the study, and randomly divided into two equal groups,who are at least 35 years of age and 16 teeth and type II diabetes are (at least the last 3 months of diagnosis of diabetes and its FBS More than 110 have), and also with periodontal disease are chronic moderate (at least in three areas Attachment level to a depth of 3-4 mm maxillary or mandibular been confirmed by clinical examination and radiographic signs are being); Takes place. The initial HbA1c Patients should be between 7-9 percent over the past three months has changed his medication also found the necessary explanations on how to do that consent, Plaque index (PI) by Loe & Silness, bleeding on probing (BOP) based on Carter and Barnes (if any bleeding number 1 and its absence is 0), probing depth (PD) and clinical attachment levels (CAL) were recorded. Group 1: (12 patients) was treated with oral hygiene instruction, Scaling, and root planing, and doxycycline for 15 days; and Group 2: (12 patients) has the same treatment but with placebo, After 12 weeks their periodontal condition and Fasting blood sugar (FBS), glycated hemoglobin (HbA1c) level, will be reevaluated.

Detailed description

Doxycycline downregulates the activity of matrix metalloproteinases (MMPs), key destructive enzymes in periodontal disease

Interventions

Oral doxycycline 100mg was taken within 15 days

DRUGplacebo Group

Oral placebo was taken within 15 days

Sponsors

Islamic Azad University, Sanandaj
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients with diabetes mellitus type II (at least 3 months before diagnosis, and A fasting blood sugar level of more than 125 mg/dl) and has periodontal disease is a chronic moderate (has a clinical attachment level of 3-4 mm) peritonitis * Minimum of 16 natural teeth, and no periodontal treatment in the prior 6 months, - Had a glycated α hemoglobin (HbA1c) value between 7- 9 percent at screening * Had reported no changes in diabetes medications within the last 3 months were in the care of a physician for their diabetes.

Exclusion criteria

* Pregnancy or lactation * History of allergy to drugs used in the study * Smoking * Diabetes-related emergency within 30 days ago * Use of nonsteroidal anti-inflammatory drugs * Or taking low dose daily aspirin (75-325 mg)\\ * Use of immunosuppressive medications; antibiotic use * Dialysis * Risk of bleeding complications * The type of disease periodontal (Aggressive) * A history of periodontal treatment in the previous 6 months * Orthodontic treatment * Using the removal prostheses * Extensive dental caries * Dental abscesses or infections.

Design outcomes

Primary

MeasureTime frameDescription
Periodontal pocket depth15 daysPeriodontal Probes Measuring (millimeters)

Secondary

MeasureTime frameDescription
glycated hemoglobin (HbA1c)3 monthsBlood test

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026